Objective? To explore the level of psychological torsion and anticipatory sorrow in patients with chronic gastroparesis and to analyze the relationship between the two. Methods? Totally 121 patients with chronic gastroparesis admitted in Xinxiang Central Hospital from April 2014 to April 2016 were selected using convenient sampling. The patients' general information was collected. The Psychological Strain Scale and the Anticipatory Sorrow Scale were used to evaluate the psychological torsion and anticipatory sorrow levels in these patients. Pearson correlation analysis and multivariate regression analysis were used to analyze the relationship between psychological torsion and anticipatory sorrow. Results? The patients' psychological torsion scored (268.94±46.14), in which the dimension of anticipatory torsion scored the highest, which was (4.61±0.44). Their anticipatory sorrow scored (35.50±5.75), in which the dimension of physical symptom scored the highest, which was (2.46±0.35). The Pearson correlation analysis showed that the total score and scores of various dimensions of psychological torsion were positively correlatively with the total score and scores of the dimensions of self-consciousness, sorrow and physical symptom of anticipatory sorrow (P＜ 0.05). According to the multivariate linear regression analysis, all the four dimensions of psychological torsion were the influencing factors to anticipatory sorrow. Conclusions? The psychological torsion and anticipatory sorrow stand at a high level in patients with chronic gastroparesis, and the two are positively correlated with each other. Psychological torsion may be used to predict anticipatory sorrow. Nurses should take active interventions to reduce the patients' psychological torsion, thereby improving their ability of mediating anticipatory sorrow.

Stargardt disease (STGD) is one of the most prevalent inherited macular dystrophy, and most often occurs in child or adolescence. Irreversible vision loss is observed in almost all cases. Type 1 (STGD1) is one of the most common type. It is an autosomal recessive condition, caused by mutations in the Abca4 gene. In recent years, encouraging progress has been made in the treatment of STGD1. C20-D3-retinyl acetate (ALK- 001), fenretinide and ICR-14967 (A1120) as visual cycle modulators, StarGen as gene supplementation therapies, and the stem cell transplantation of human embryonic stem cell-derived retinal pigment epithelium cells are the most promising therapies. With the development of studies and clinical trials, the clinical application of various treatments of STGD1 are expected in the near feature, which are expected to save the vision of most patients.